\n<\/p>\n
The Switzerland stock market bucked the weak trend seen across Europe on Monday, but ended just marginally up despite spending much of the day’s session in positive territory.<\/p>\n
Buying interest was subdued due to a lack of positive triggers.<\/p>\n
The benchmark SMI ended with a small gain of 9.47 points or 0.08% at 12,009.17, after moving in a tight band between 11,986.88 and 12,025.95.<\/p>\n
Roche Holding ended nearly 1% up. Lonza Group gained 0.85%, while Sika, Swisscom and Novartis moved up 0.3 to 0.4%.<\/p>\n
Holcim and Credit Suisse shed 1.76% and 1.56%, respectively. Swatch Group ended 1.19% down, while Swiss Re and UBS Group both ended lower by nearly 1%. Swiss Life Holding and Partners Group lost 0.7% and 0.5%, respectively.<\/p>\n
In the Swiss Mid Price Index, BB Biotech, Lindt & Spruengli, AMS, SIG Combibloc, Schindler Ps and Galenica Sante gained 0.4 to 0.8%.<\/p>\n
Dufry declined nearly 8% and Flughafen Zurich ended lower by 3.5%. Julius Baer shed 2.7% and Helvetia lost 2.4%. Cembra Money Bank and Vifor Pharma both shed about 1.4%.<\/p>\n
The Swiss government announced recently that from June 26th anyone fully vaccinated can enter Switzerland for tourism or a visit. However, conditions may apply including testing or quarantine, particularly for people arriving from countries with variants of significant concern. <\/p>\n
Meanwhile, the vaccination rollout in Switzerland has slowed slightly, dropping by 7% to 82,700 jabs per day, compared to the previous week. According to reports, over 32% of the country’s population are fully vaccinated. <\/p>\n<\/p>\n
Market Analysis<\/p>\n<\/div>\n